SGP acquires U.S. rights to Integrilin

Schering-Plough (SGP) acquired from Millennium (MLNM) exclusive U.S. rights to Integrilin eptifibatide to treat acute coronary syndromes. MLNM will receive $35.5 million up front, plus royalties. In 2006 and 2007, the minimum royalty is $85 million. SGP also will pay MLNM $45-$50 million for existing inventory. In 2004, Integrilin sales were $325 million, including $301 million in the U.S. ...